• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

骨髓瘤治疗方法及其对口腔颌面副作用的潜在影响综述。

Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects.

作者信息

Beaumont Sophie, Harrison Simon, Er Jeremy

机构信息

Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

Melbourne Dental School, University of Melbourne, Melbourne, VIC 3000, Australia.

出版信息

Cancers (Basel). 2021 Sep 6;13(17):4479. doi: 10.3390/cancers13174479.

DOI:10.3390/cancers13174479
PMID:34503289
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8431464/
Abstract

Myeloma is a common haematological malignancy in which adverse skeletal related events are frequently seen. Over recent years, treatment for myeloma has evolved leading to improved survival. Antiresorptive therapy is an important adjunct therapy to reduce the risk of bone fractures and to improve the quality of life for myeloma patients; however, this has the potential for unwanted side effects in the oral cavity and maxillofacial region. Osteonecrosis of the jaw related to antiresorptive medications and other myeloma therapies is not uncommon. This review serves to highlight the risk of osteonecrosis of the jaw for myeloma patients, with some suggestions for prevention and management.

摘要

骨髓瘤是一种常见的血液系统恶性肿瘤，常出现不良骨骼相关事件。近年来，骨髓瘤的治疗有所进展，生存率得以提高。抗吸收治疗是一种重要的辅助治疗手段，可降低骨髓瘤患者骨折风险并改善生活质量；然而，这种治疗在口腔和颌面部区域可能会产生不良副作用。与抗吸收药物及其他骨髓瘤治疗相关的颌骨骨坏死并不罕见。本综述旨在强调骨髓瘤患者发生颌骨骨坏死的风险，并提出一些预防和管理建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bae/8431464/39a2a9fadd96/cancers-13-04479-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bae/8431464/a0286d584159/cancers-13-04479-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bae/8431464/ed1d9008e479/cancers-13-04479-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bae/8431464/a7ba1df2db55/cancers-13-04479-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bae/8431464/39a2a9fadd96/cancers-13-04479-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bae/8431464/a0286d584159/cancers-13-04479-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bae/8431464/ed1d9008e479/cancers-13-04479-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bae/8431464/a7ba1df2db55/cancers-13-04479-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8bae/8431464/39a2a9fadd96/cancers-13-04479-g004a.jpg

相似文献

1
Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects.骨髓瘤治疗方法及其对口腔颌面副作用的潜在影响综述。
Cancers (Basel). 2021 Sep 6;13(17):4479. doi: 10.3390/cancers13174479.
2
Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.上颌骨骨质坏死与口腔暴露：双膦酸盐治疗多发性骨髓瘤的影响
Acta Med Port. 2007 Mar-Apr;20(2):185-92. Epub 2007 Jun 11.
3
Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature.潜在药物相关性颌骨坏死风险的新兴疗法：文献综述。
Br Dent J. 2020 Jun;228(11):886-892. doi: 10.1038/s41415-020-1642-3.
4
Platelet rich fibrin in the management of medication-related osteonecrosis of the jaw: a clinical and histopathological evaluation.富血小板纤维蛋白在药物相关性颌骨坏死治疗中的应用：一项临床和组织病理学评估
J Biol Regul Homeost Agents. 2017 Jul-Sep;31(3):811-816.
5
Medication-related osteonecrosis of the jaw: Clinical and practical guidelines.药物相关性颌骨坏死：临床与实践指南
J Int Soc Prev Community Dent. 2016 Mar-Apr;6(2):97-104. doi: 10.4103/2231-0762.178742.
6
Is the prevalence of the medication-related osteonecrosis of the jaws underestimated, evaluation in oncological and non-oncological disease.颌骨药物相关性骨坏死的患病率是否被低估：肿瘤及非肿瘤疾病中的评估
Bratisl Lek Listy. 2017;118(12):724-731. doi: 10.4149/BLL_2017_137.
7
Multiple myeloma and chemical maxillary osteonecrosis. Can both occur simultaneously?多发性骨髓瘤与化学性上颌骨骨坏死。两者可同时发生吗？
J Stomatol Oral Maxillofac Surg. 2020 Nov;121(5):523-526. doi: 10.1016/j.jormas.2019.12.002. Epub 2019 Dec 18.
8
Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw.颌骨药物性骨坏死风险患者的预防策略
Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):527-36. doi: 10.1016/j.coms.2015.06.006. Epub 2015 Aug 18.
9
Medication-related Osteonecrosis of the Jaw: A Review.药物相关性颌骨坏死：综述
Cureus. 2020 Feb 10;12(2):e6944. doi: 10.7759/cureus.6944.
10
Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.药物相关性颌骨坏死：双膦酸盐治疗患者与抗吸收-抗血管生成药物治疗患者的风险因素
Minerva Stomatol. 2017 Aug;66(4):135-140. doi: 10.23736/S0026-4970.17.04056-0. Epub 2017 May 10.

引用本文的文献

1
Identification of Potentially Pathogenic Variants Associated with Recurrence in Medication-Related Osteonecrosis of the Jaw (MRONJ) Patients Using Whole-Exome Sequencing.使用全外显子组测序鉴定与颌骨药物相关性骨坏死（MRONJ）患者复发相关的潜在致病变异体。
J Clin Med. 2022 Apr 12;11(8):2145. doi: 10.3390/jcm11082145.
2
Myeloma: A Lot of Progress, Still a Long Way to Go.骨髓瘤：虽已取得诸多进展，但仍任重道远。
Cancers (Basel). 2021 Dec 2;13(23):6087. doi: 10.3390/cancers13236087.

本文引用的文献

1
Oral health condition in cancer patients under bisphosphonate therapy.癌症患者双膦酸盐治疗中的口腔健康状况。
Support Care Cancer. 2021 Dec;29(12):7687-7694. doi: 10.1007/s00520-021-06362-y. Epub 2021 Jun 18.
2
Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.药物相关性颌骨坏死的临床注意事项：全面文献回顾。
Int J Implant Dent. 2021 May 14;7(1):47. doi: 10.1186/s40729-021-00323-0.
3
Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.
基于靶向蛋白降解的癌症疗法——来那度胺的经验教训。
Nat Rev Clin Oncol. 2021 Jul;18(7):401-417. doi: 10.1038/s41571-021-00479-z. Epub 2021 Mar 2.
4
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.地舒单抗对比唑来膦酸在多发性骨髓瘤患者中的 PFS：一项国际 3 期研究的探索性结果。
Blood Adv. 2021 Feb 9;5(3):725-736. doi: 10.1182/bloodadvances.2020002378.
5
A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy.意大利西北部一个癌症网络中晚期癌症和骨髓瘤患者颌骨药物相关性骨坏死（MRONJ）的多中心观察性研究。
Med Oral Patol Oral Cir Bucal. 2021 Jul 1;26(4):e466-e473. doi: 10.4317/medoral.24318.
6
The Case of Medication-Related Osteonecrosis of the Jaw Addressed from a Pathogenic Point of View. Innovative Therapeutic Strategies: Focus on the Most Recent Discoveries on Oral Mesenchymal Stem Cell-Derived Exosomes.从发病机制角度探讨药物相关性颌骨坏死病例。创新治疗策略：聚焦口腔间充质干细胞衍生外泌体的最新发现。
Pharmaceuticals (Basel). 2020 Nov 25;13(12):423. doi: 10.3390/ph13120423.
7
Medication-related osteonecrosis of the jaw: Analysing the range of implicated drugs from the Australian database of adverse event notifications.药物相关性颌骨坏死：基于澳大利亚不良事件通报数据库分析相关药物范围
Br J Clin Pharmacol. 2021 Jul;87(7):2767-2776. doi: 10.1111/bcp.14681. Epub 2020 Dec 16.
8
Management of Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Leukocyte- and Platelet-Rich Fibrin (L-PRF) and Photobiomodulation: A Retrospective Study.使用富含白细胞和血小板的纤维蛋白（L-PRF）及光生物调节疗法治疗颌骨药物相关性骨坏死（MRONJ）：一项回顾性研究
J Clin Med. 2020 Oct 29;9(11):3505. doi: 10.3390/jcm9113505.
9
Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and/or Targeted Drugs Increases the Risk for Stage 3 Medication-Related Osteonecrosis of the Jaw: A 4-Year Retrospective Study.联合应用双膦酸盐、化疗药物和/或靶向药物会增加 3 级药物相关性颌骨坏死的风险：一项为期 4 年的回顾性研究。
Biomed Res Int. 2020 Oct 15;2020:5847429. doi: 10.1155/2020/5847429. eCollection 2020.
10
Pentoxifylline and tocopherol protocol to treat medication-related osteonecrosis of the jaw: A systematic literature review.己酮可可碱和生育酚方案治疗药物相关性颌骨坏死：系统文献复习。
J Craniomaxillofac Surg. 2020 Nov;48(11):1080-1086. doi: 10.1016/j.jcms.2020.09.008. Epub 2020 Sep 18.